<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>GHK-Cu: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-ghk-cu</link>
    <atom:link href="https://greypeptides.com/changes/ghk-cu.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about GHK-Cu on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-ghk-cu</link>
      <guid isPermaLink="false">greypeptides-changes-ghk-cu-guide-/testing/#c-ghk-cu</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>Regulatory alert: Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.</title>
      <link>https://greypeptides.com/regulatory/alerts/#anvisa-peptides-not-registered</link>
      <guid isPermaLink="false">greypeptides-changes-ghk-cu-alert-anvisa-peptides-not-registered</guid>
      <pubDate>Thu, 02 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules.</description>
    </item>
    <item>
      <title>Regulatory alert: France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ansm-peptides-online-warning</link>
      <guid isPermaLink="false">greypeptides-changes-ghk-cu-alert-ansm-peptides-online-warning</guid>
      <pubDate>Thu, 02 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA put GHK-Cu, except for injectable routes, back in 503A Category 1, after a nominator clarified on May 5 that it had withdrawn only the injectable nomination.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ghk-cu-non-injectable-category-1</link>
      <guid isPermaLink="false">greypeptides-changes-ghk-cu-alert-ghk-cu-non-injectable-category-1</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>503A pharmacies may compound GHK-Cu for non-injectable use under Category 1 while FDA decides; injectable GHK-Cu is in no category and cannot be compounded. FDA plans to take GHK-Cu to the committee before the end of February 2027.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-second-meeting-planned</link>
      <guid isPermaLink="false">greypeptides-changes-ghk-cu-alert-pcac-second-meeting-planned</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.</description>
    </item>
  </channel>
</rss>
